|1.||Rey, Juan A: 10 articles (01/2012 - 03/2003)|
|2.||Gjerset, Ruth A: 9 articles (01/2013 - 10/2002)|
|3.||Rizos, Helen: 9 articles (02/2010 - 02/2003)|
|4.||Kefford, Richard F: 9 articles (02/2010 - 02/2003)|
|5.||Bello, M Josefa: 9 articles (02/2006 - 03/2003)|
|6.||Alonso, M Eva: 7 articles (11/2004 - 03/2003)|
|7.||Gonzalez-Gomez, Pilar: 7 articles (11/2004 - 03/2003)|
|8.||Tannapfel, Andrea: 7 articles (08/2004 - 02/2002)|
|9.||Shimada, Keiji: 6 articles (01/2008 - 04/2002)|
|10.||Ishida, Eiwa: 6 articles (01/2008 - 04/2002)|
06/01/2005 - "On multivariate analysis, p14(ARF) positivity (nucleolar p14(ARF) staining and/or nuclear p14(ARF) staining in >/=30% of tumor cells) was an independent predictor of improved disease-free survival (DFS; P = 0.002) and overall survival (OS; P = 0.002). "
07/01/2003 - "The results indicate that endogenous p14ARF expression may be insufficient to ensure efficient accumulation of ectopic p53 after gene transfer and demonstrate that for tumor suppression, bicistronic coexpression of p14ARF and p53 is superior to p53 alone. "
06/01/2014 - "The methylation of p14ARF promoter was detected in 33.6 % of tumor tissues, and 12.1 and 25.2 % in distant-cancer mucosa and matched plasma, respectively, and our study has also demonstrated the positive correlation between them by Pearson's test (r = 0.300). "
11/01/2001 - "The immunohistochemical assay described here may facilitate studies on the prevalence and significance of aberrant p14(ARF) expression in human tumors."
02/01/2016 - "The tumor suppressor p14(ARF) is overexpressed in response to oncogenic stimuli to stabilize p53 halting cell progression. "
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/01/2007 - "Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC)."
02/01/2014 - "The objective of this study is to evaluate the promoter methylation status of the p14ARF in esophageal squamous cell carcinoma (ESCC). "
01/01/2013 - "This study was designed to determine the prognostic role of p14ARF in vulvar squamous cell carcinoma (VSCC). "
03/01/2015 - "Epigenetic changes in the CDKN2A locus are associated with differential expression of P16INK4A and P14ARF in HPV-positive oropharyngeal squamous cell carcinoma."
01/01/2015 - "To evaluate the association of MMP11 and P14(ARF) expression in laryngeal squamous cell carcinoma (LSCC) with clinical pathological characteristics and survival. "
01/01/2003 - "We evaluated and compared the relative potential therapeutic efficacy of p14ARF and p16INK4A expressed in adenoviral vectors (Adp14ARF and Adp16INK4A, respectively) in three human mesothelioma cell lines. "
04/19/2000 - "We designed this study to evaluate the biologic and potential therapeutic roles of p14(ARF) expression in mesothelioma cells. "
01/01/2008 - "Disruption of the 9p21 locus is common in mesothelioma and leads to loss of both the p16INK4a and the p14ARF gene products. "
07/01/2006 - "p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma."
12/01/2005 - "In both mouse and human mesothelioma cells, inactivation of the hortologous genes p16/Cdkn2a or P16/CDKN2A was due to deletions at the Ink4/Arf locus encompassing p19/Arf or P14/ARF, respectively. "
|4.||Neoplasm Metastasis (Metastasis)
01/01/2013 - "Mainly due to the relationship of p14ARF with lymph node metastasis, the immunohistochemistry evaluation of this marker may help to identify a subset of patients more suitable to less radical procedures."
01/01/2013 - "The hypermethylation of p14ARF showed a significant association with the absence of metastases at diagnoses, while ESR1 hypermethylation was marginally associated with worse overall survival. "
01/01/2012 - "Taken together, our findings provide the new evidence that overexpression of CDK5RAP3 promotes HCC metastasis via downregulation of p14(ARF)."
02/01/2014 - "p14ARF repression induced by promoter methylation associated with metastasis in esophageal squamous cell carcinoma."
05/01/2013 - "Further analysis showed that in GCA, the negative expression of p14ARF was significantly associated with poor differentiation, Mdm2 overexpression with tumor stage and lymph node metastasis, and positive p53 expression with tumor stage (P < .05), whereas in DGA, only Mdm2 overexpression was related with well/moderate differentiation (P < .05). "
|5.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
07/01/1999 - "We studied bone marrow samples of 42 newly diagnosed and untreated patients with acute lymphoblastic leukemia for the incidence of deletions of p16INK4a/p14ARF and p15INK4b using Southern blot analysis and determined the clinical outcome with regard to complete remission (CR) duration, event-free survival, and overall survival. "
07/01/1999 - "The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia."
11/01/2004 - "Multiplex methylation-sensitive PCR and methylation-specific PCR were employed in studying the methylation of CpG islands in the p16/CDKN2A and p14/ARF promoter and the first exon regions in non-small cell lung cancer (54 samples) and acute B-cell lymphoblastic leukemia (61 samples). "
09/01/1999 - "The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia."
05/13/2002 - "A broad spectrum of tumor suppressor gene alterations do occur in hematological malignancies, especially structural alterations of p15(INK4A), p15(INK4B) and p14(ARF) in acute lymphoblastic leukemia as well as methylation of these genes in several myeloproliferative disorders. "
|1.||Complementary DNA (cDNA)
|2.||Cyclin-Dependent Kinase Inhibitor p16
|3.||Messenger RNA (mRNA)
|4.||Proteins (Proteins, Gene)
|5.||DNA (Deoxyribonucleic Acid)
|6.||Telomerase (Telomerase Reverse Transcriptase)
|9.||Tumor Suppressor Proteins (Proteins, Tumor Suppressor)
|10.||Proto-Oncogene Proteins c-mdm2
|1.||Heterologous Transplantation (Xenotransplantation)
|5.||Prostatectomy (Retropubic Prostatectomy)